Stoke Therapeutics Inc
STOKHealthcare|Biotechnology|USA
$31.38
-1.47 (-4.47%)
Tangible Book
$6.34
About
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Stock Price
+160.6%(1Y)
Pipeline Summary
7 total trials1
Phase 1
3
Phase 2
1
Phase 3
2
Phase 4
Completed: 4Recruiting: 2Active: 1
Active Trials (3)
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
Phase 3Recruiting
Enrollment: 170 participants
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
NCT04740476Dravet Syndrome
Phase 2Active
Enrollment: 60 participants
Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation
NCT05615766Spinal Cord Injuries
N/ARecruiting
Enrollment: 9 participants
BioScore
4.8/10
Cautious
Ownership
Recent Insider Trades
Ticho BarrySELL
2026-07-017,228 shares @ $32.66
Allan JonathanSELL
2026-06-161,457 shares @ $29.95
Ticho BarrySELL
2026-06-011,795 shares @ $30.58
Ticho BarrySELL
2026-05-012,243 shares @ $32.79
Ticho BarrySELL
2026-04-011,838 shares @ $32.66
Recent News
2026-07-13 12:00:07
2026-07-13 10:36:09
2026-06-30 14:12:14
2026-06-30 12:35:17
2026-06-30 12:01:51
Data last updated: Jul 13, 2026, 12:44 PM